Department of Colorectal Surgery, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
Department of Colorectal Surgery, Haut-Lévèque Hospital, CHU Bordeaux, Pessac, France.
Colorectal Dis. 2023 Jun;25(6):1153-1162. doi: 10.1111/codi.16535. Epub 2023 Mar 18.
AIM: The standard strategy for clinical T3 rectal cancer without enlarged lateral lymph nodes is preoperative chemoradiotherapy (CRT) followed by total mesorectal excision (TME) in Western countries and TME with bilateral lateral pelvic lymph node dissection (LPLND) in Japan. This study compared surgical, pathological and oncological results of these two strategies. METHOD: Patients who underwent preoperative CRT followed by TME in France (CRT + TME group) and those who underwent TME with LPLND in Japan (TME + LPLND group) for clinical T3 rectal adenocarcinoma without enlarged lateral lymph nodes from 2010 to 2016 were retrospectively analysed. RESULTS: In total, 439 patients were included in this study. The estimated local recurrence rate (LRR), disease-free survival and overall survival at 5 years post-surgery was 4.9%, 71% and 82% in the CRT + TME group, and 8.6%, 75% and 90% in the TME + LPLND group, respectively. Lateral LRR versus non-lateral LRR was 0.5% versus 4.2% in the CRT + TME group and 1.8% versus 6.2% in the TME + LPLND group. Obturator nerve injury and isolated pelvic abscess were shown only in the TME + LPLND group. Urinary complications were more frequent in the TME + LPLND group than in the CRT + TME group. CONCLUSION: Disease-free survival was not significantly different after TME with LPLND and after CRT followed by TME. LRR was not significantly different after both strategies; however, there was a trend for higher LRR after TME with LPLND than after CRT followed by TME. Obturator nerve injury, isolated lateral pelvic abscess and urinary complications should be noted when TME with LPLND is applied.
目的:对于无侧方淋巴结肿大的临床 T3 直肠腺癌,西方国家的标准治疗策略是术前放化疗(CRT)后行全直肠系膜切除术(TME),日本则是 TME 联合双侧侧方骨盆淋巴结清扫术(LPLND)。本研究比较了这两种策略的手术、病理和肿瘤学结果。
方法:回顾性分析了 2010 年至 2016 年间在法国行术前 CRT 后行 TME(CRT+TME 组)和在日本行 TME 联合 LPLND(TME+LPLND 组)治疗无侧方淋巴结肿大的临床 T3 直肠腺癌患者的资料。
结果:本研究共纳入 439 例患者。术后 5 年的局部复发率(LRR)、无病生存率和总生存率估计值分别为 CRT+TME 组 4.9%、71%和 82%,TME+LPLND 组 8.6%、75%和 90%。在 CRT+TME 组,侧方 LRR 与非侧方 LRR 分别为 0.5%和 4.2%;在 TME+LPLND 组,分别为 1.8%和 6.2%。闭孔神经损伤和孤立性骨盆脓肿仅见于 TME+LPLND 组。TME+LPLND 组的尿路并发症较 CRT+TME 组更为常见。
结论:LPLND 后 TME 与 CRT 后行 TME 的无病生存率无显著差异。两种策略后的 LRR 无显著差异;然而,LPLND 后 TME 的 LRR 有高于 CRT 后行 TME 的趋势。行 LPLND 时应注意闭孔神经损伤、孤立性侧方骨盆脓肿和尿路并发症。
World J Gastroenterol. 2020-6-7
Tech Coloproctol. 2025-1-23